By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Ipsen 

39, rue du Bois Chaland

Evry Cedex    91029  France
Phone: 33-1-608-72600 Fax: 33-1-608-61609


SEARCH JOBS


Industry
Pharmaceutical






Company News
Ipsen (IPN.PA) Agrees to Hire 100 Merrimack (MACK) Employees Under $575 Million Cancer Deal 2/15/2017 6:58:00 AM
Sanofi (SNY) Unloads Five OTC Drugs to Ipsen (IPN.PA) for $88 Million to Pave Way for Boehringer Ingelheim Deal 2/13/2017 5:55:35 AM
Ipsen (IPN.PA) To Acquire Primary Care Platform In Italy From Akkadeas Pharma 1/31/2017 11:17:43 AM
Ipsen (IPN.PA) Release: Monthly Information Regarding The Total Number Of Voting Rights And Total Number Of Shares Of The Company 1/10/2017 11:10:43 AM
Ipsen (IPN.PA) to Acquire Oncology Assets From Merrimack (MACK) for $575 Million 1/9/2017 1:06:21 PM
Ipsen (IPN.PA) Amends Licensing Agreement With Exelixis (EXEL) To Commercialize And Develop Cabozantinib In Canada 12/22/2016 1:23:00 PM
Exelixis (EXEL) And Ipsen (IPN.PA) Amend Exclusive Licensing Agreement For The Commercialization And Development Of Cabozantinib To Include Canada 12/21/2016 9:29:26 AM
Claude Bertrand to Step Down as Executive Vice President, R&D and CSO of Ipsen (IPN.PA) 12/12/2016 6:19:31 AM
Ipsen (IPN.PA) Reports 12.2%1 Sales Growth For The Third Quarter Of 2016 And Raises Full Year Guidance 10/26/2016 10:06:31 AM
Ipsen (IPN.PA) And Its Partner Exelixis (EXEL) Announce Positive Results From Phase 2 CABOSUN Trial Of Cabozantinib Versus Sunitinib In Previously Untreated Advanced Renal Cell Carcinoma Presented At The European Society For Medical Oncology (ESMO) 2016 Congress 10/10/2016 11:55:27 AM
12345678910...
//-->